Skip to content

Study · Animal study (in vivo) · steers · 1988

2 results

Use of osmotic pumps for subcutaneous infusion of growth hormone-releasing factors in steers and wethers.

Wheaton JE, al-Raheem SN, Godfredson JA, Dorn JM, Wong EA, Vale W, Rivier J, Mowles TF, Heimer EP, Felix AM

Journal of animal science1 Nov 1988Cited by 4 (Europe PMC)

PMID2906350 (opens in a new tab)DOI10.2527/jas1988.66112876x (opens in a new tab)PepBankPUB-02906350
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In steers, 7-day subcutaneous infusion of hGRF(1-29)NH2 by osmotic pump did not alter growth hormone levels.

    In plain wordsIn steers, a week of continuous infusion of this growth hormone-releasing peptide did not change growth hormone levels.

    Peptide
    Sermorelin
    Outcome
    No significant changeGrowth hormone levels (Exp. 1)
    Study

    steersn = 12

    Comparator
    Control (0 pmol.h-1.kg-1)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0, 3, 30 and 300 pmol.h-1.kg-1 · subcutaneous infusion by osmotic pump · 7 daysAs given in this study (steers).

    Source sentences

    Summary
    Growth hormone levels were not altered by GRF treatment (P greater than .05).
    2 context sentences
    Summary · context
    1, 12 steers weighing 253 kg received hGRF(1-29)NH2 in H2O at rates of 0, 3, 30 and 300 pmol.h-1.kg-1.
    Summary · context
    Pumps were implanted s.c. on d 0 and removed at 1200 on d 7.

Studies that did not test the peptide alone1

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 02AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Other

    In steers, solubility and volume limitations made delivery of hGRF(1-29)NH2 by osmotic pump problematical.

    In plain wordsIn steers, osmotic pumps were hard to use for this peptide because of solubility and volume limits.

    Peptide
    Sermorelin
    Outcome
    Not applicableOsmotic pump delivery of hGRF(1-29)NH2 (solubility and volume limits)
    Study

    steersn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Solubility and volume limitations render hGRF(1-29)NH2 delivery via osmotic pumps problematical.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.